Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163301 | 0.84 | AHR (0.53) | CYP11B1CYP11B2CYP1A2AHRALDH1A1 | |
| SCHEMBL9378752 | 0.81 | CYP11B1 (0.52) | CYP11B1CYP11B2CYP1A2CA9AHR | |
| SCHEMBL428384 | 0.80 | CYP11B1 (0.51) | CYP11B1CYP11B2CYP1A2CA9AHR | |
| SCHEMBL14779528 | 0.79 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP1A2CA9AHR | |
| SCHEMBL12559608 | 0.79 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP1A2CA9AHR | |
| SCHEMBL7268522 | 0.79 | CA9 (0.46) | CYP11B1CYP11B2CYP1A2CA9CYP19A1 | |
| SCHEMBL8553375 | 0.79 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP1A2CA9AHR | |
| SCHEMBL27141349 | 0.79 | CA9 (0.46) | CYP11B1CYP11B2CYP1A2CA9SRD5A1 | |
| SCHEMBL27136456 | 0.76 | CA9 (0.44) | CYP11B1CYP11B2CYP1A2CA9CYP3A4 | |
| SCHEMBL19737432 | 0.75 | CYP11B1 (0.47) | CYP11B1CYP11B2CYP1A2CA9AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343709-A1 | SUBSTITUTED HETEROCYCLES AS ALDEHYDE DEHYDROGENASE INHIBITORS | THE TRUSTEES OF PRINCETON UNIVERSITY | 2024-10-17 | — | — | US | disclosed |
| US-12054475-B2 | Substituted heterocycles as aldehyde dehydrogenase inhibitors | KAYOTHERA INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240132469-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KAYOTHERA INC. (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117897370-A | Heterocyclic compounds and their use | 凯悦施那有限公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4326696-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kayothera Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022226383-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KAYOTHERA INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| EP-0370381-B1 | 2(1H)-quinolinone compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-05-10 | — | — | EP | disclosed |
| US-4988698-A | Cardiovascular disorders, hypotensive agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-29 | — | — | US | disclosed |
| EP-0370381-A2 | 2(1H)-quinolinone compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343709-A1 | SUBSTITUTED HETEROCYCLES AS ALDEHYDE DEHYDROGENASE INHIBITORS | ALDH3A1, ALDH2, ALDH1A2 | CYP11B1 60/4885CYP11B2 30/4885CYP1A2 147/4885 |
| US-12054475-B2 | Substituted heterocycles as aldehyde dehydrogenase inhibitors | ALDH3A1, ALDH2, ALDH1A2 | CYP11B1 60/4885CYP11B2 30/4885CYP1A2 147/4885 |
| US-20240132469-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, ALDH2, PDK1 | CYP11B1 4/4885CYP11B2 1/4885CYP1A2 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.